Nephros, Inc. (NEPH) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
Nephros reported strong revenue growth of 33% and improved net income and adjusted EBITDA, despite challenges like tariff impacts and increased R&D and SG&A expenses. The company's expansion into new markets and strong customer retention are promising. However, the Q&A section revealed some vagueness in management's responses, which could be a concern. Overall, the strong financial performance and strategic growth initiatives outweigh the negatives, suggesting a positive stock price movement.
Key Financial Performance
Revenue Growth Nephros delivered 33% revenue growth in 2025, reaching $18.8 million in total revenue, compared to $14.2 million in 2024. This increase was primarily driven by higher programmatic revenue, strong reorder activity, and the addition of several new active sites.
Net Income Net income for 2025 was approximately $1.2 million, compared to $0.1 million in 2024. The improvement was largely due to increased sales revenue.
Gross Margin Gross margin was 62% for both 2025 and 2024. However, gross margin for Q4 2025 was 58%, down from 64% in Q4 2024, primarily due to the impact of tariffs on goods imported from Italy.
Adjusted EBITDA Adjusted EBITDA for 2025 was a positive $1.6 million, compared to $548,000 in 2024. For Q4 2025, adjusted EBITDA was $131,000, compared to $481,000 in Q4 2024.
Net Cash Provided by Operating Activities Net cash provided by operating activities was $1.6 million in 2025, compared to net cash used of $0.5 million in 2024. This was primarily due to net income of $1.2 million, an increase in accrued expenses, and accounts payable, offset by increases in accounts receivable and inventory.
Cash Balance Cash balance as of December 31, 2025, was $5.4 million, compared to $3.8 million as of December 31, 2024. The company remains debt-free.
Research and Development Expenses R&D expenses for 2025 were $1.3 million, up from $0.9 million in 2024, a 44% increase, primarily due to higher headcount and bonuses.
Selling, General, and Administrative Expenses SG&A expenses for 2025 were $9 million, up from $7.7 million in 2024, a 17% increase, due to higher bonuses and sales commissions. For Q4 2025, SG&A expenses were $2.3 million, up from $1.9 million in Q4 2024, a 24% increase, also due to bonuses, sales commissions, and one-time expenses related to product development and market analysis.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Product Innovation: Launched advanced filtration technologies for new applications such as ice machines, drinking fountains, bottle filling stations, and sterile processing environments. These innovations expand the addressable market beyond traditional patient care applications.
Market Expansion: Progress in non-patient care applications and plans to penetrate residential and commercial markets through key relationships.
Revenue Growth: Achieved 33% revenue growth in 2025, reaching $18.8 million, with strong reorder activity and growth in active customer sites.
Profitability: Reported net income of $1.2 million in 2025, marking the second consecutive year of profitability.
Service Expansion: Expanded installation and replacement capabilities, offering a complete lifecycle solution for water filtration systems, which supports recurring revenue.
Three-Pillar Strategy: Focused on products, services, and education to drive growth and establish leadership in water safety solutions.
Educational Initiatives: Launched the Nephros Water Institute to provide training and webinars, enhancing knowledge on waterborne pathogen mitigation and compliance-driven filtration solutions.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Tariffs on imported goods: Since April 2025, Nephros has been subject to a 15% tariff on all goods imported from Italy, which was reduced to 10% in February 2026. However, U.S. tariff policy remains unpredictable, creating uncertainty around potential future margin impacts.
Gross margin erosion: Gross margins eroded during the second half of 2025, primarily due to the impact of tariffs, which could affect profitability.
Increased R&D expenses: Research and development expenses increased by 57% in Q4 2025 compared to Q4 2024, driven by higher headcount and bonuses, which could strain financial resources.
Higher SG&A expenses: Selling, general, and administrative expenses increased by 17% in 2025 compared to 2024, due to higher bonuses and sales commissions, as well as one-time expenses for product development and market analysis, potentially impacting profitability.
Inventory and accounts receivable increases: Increases in accounts receivable and inventory in 2025 could tie up cash flow and create operational challenges.
Regulatory and compliance risks: The company faces rising regulatory expectations around water safety, which could increase compliance costs and operational complexity.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Future Market Expansion: Nephros plans to develop channels to penetrate residential and commercial markets through key relationships, expanding beyond traditional patient care applications.
Product Innovation Pipeline: The company is focusing on new product launches to address high-impact applications such as ice machines, drinking fountains, bottle filling stations, and sterile processing environments, aiming to expand its addressable market.
Service Expansion: Nephros is enhancing its service offerings, including installation, replacement programs, and technical support, to reduce barriers to adoption and strengthen long-term customer relationships. This model supports recurring revenue through programmatic filter replacements.
Educational Initiatives: The Nephros Water Institute aims to expand knowledge on waterborne pathogen mitigation and compliance-driven filtration solutions, building long-term demand for the company's products and services.
Market Trends and Positioning: The company is positioned to benefit from trends such as increased awareness of waterborne pathogens, rising regulatory expectations, aging infrastructure in healthcare and hospitality, and the growing need for reliable filtration solutions.
Tariff Impact and Margin Uncertainty: While the reduction of tariffs on goods imported from Italy provides near-term relief, U.S. tariff policy remains unpredictable, creating uncertainty around future margin impacts.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What percent of revenues for the fourth quarter and the full year were programmatic sales, and what is the outlook for 2026?
A:Programmatic sales accounted for over 90% of the business in the fourth quarter and for the year. Emergency response sales grew in high single digits but were less significant. The company anticipates continued growth in programmatic sales.
Q:What is the count of active customer sites as of 12/31/2025?
A:The active customer sites were just under 1,700, specifically 1,681 sites, reflecting significant growth due to customer retention efforts and outreach.
Q:What are the opportunities outside of medical, in the commercial space, and how do you see that evolving in 2026 or the next few years?
A:The company is focusing on non-patient care markets like hospitality, restaurants, correctional facilities, schools, and aviation facilities. Growth in these areas depends on education and overcoming barriers like perceived complexity of installation. This is a multiyear strategy, and while these markets are not yet a significant part of the business, they are expected to grow.
Q:Can you elaborate on successes in newer markets outside of hospitals and medical facilities?
A:Successes have been seen in correctional facilities, schools, aviation facilities, drinking water fountains, sterile processing facilities, eyewash stations, and emergency showers. The company has hosted seminars with over 1,000 attendees to educate and build trust in these markets.
Q:Review of Unclear Management Responses
A:Management avoided providing exact numbers for programmatic sales and emergency response sales, using vague terms like '90% plus' and 'high single digits.' Additionally, while discussing opportunities in non-medical markets, the responses were broad and lacked specific data or timelines.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Conference today
Selling increase
Services
Smith
Water
account increase
addition
bonus sale
capability
care application
care hospitality
compliance
core pillar
demand
end
expertise
filtration solution
health care
increase account
increase bonus
increase inventory
installation replacement
knowledge
life
model filter
need
pathogen
program
relationship
sale commission
service education
solution product
tariff
training
water safety
work
NEPH Transcript
Nephros, Inc. (NEPH) Q4 2025 Earnings Call Transcript
Positive3-12
Nephros reported strong revenue growth of 33% and improved net income and adjusted EBITDA, despite challenges like tariff impacts and increased R&D and SG&A expenses. The company's expansion into new markets and strong customer retention are promising. However, the Q&A section revealed some vagueness in management's responses, which could be a concern. Overall, the strong financial performance and strategic growth initiatives outweigh the negatives, suggesting a positive stock price movement.
Nephros, Inc. (NEPH) Q3 2025 Earnings Call Transcript
Positive11-7
Nephros shows strong financial performance with significant improvements in net income and adjusted EBITDA. The strategic expansion into underserved markets, innovative product launches, and maintaining a solid cash position are positive indicators. The Q&A highlights growth drivers in infection control and innovations tackling PFAS and microplastics, with a positive outlook on margins despite tariffs. However, lack of specific guidance on PFAS revenue and tariff impacts slightly tempers enthusiasm. Overall, the company's strategic initiatives and financial health suggest a positive stock price movement.
Nephros, Inc. (NEPH) Q2 2025 Earnings Call Transcript
Positive8-8
The earnings call highlights strong financial performance with significant revenue growth and improved profitability. While there are risks such as regulatory challenges and supply chain costs, the company's operational discipline and strategic expansion efforts are promising. The Q&A section suggests a sustainable growth model and effective resource allocation. Despite the need for sales force expansion, the overall sentiment remains positive due to strong financial metrics and optimistic guidance.
Earnings call transcript: Nephros Q4 2024 beats EPS forecast, stock surges
Positive3-7
The earnings call reveals strong financial performance with increased revenue, improved margins, and positive net income, despite some economic and competitive pressures. The company's strategic initiatives, including market expansion and digital tool development, are progressing well. The Q&A section indicates potential growth opportunities, although some responses were vague. The absence of shareholder return plans is a minor negative. Overall, the positive financial results and strategic growth initiatives suggest a positive stock price movement.
NEPH Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
